managing-pediatric-behavioral-health

# Managing Pediatric Behavioral Health

Screens for and manages common pediatric behavioral and emotional conditions including anxiety, depression, disruptive behavior disorders, trauma/adverse childhood experiences (ACEs), and autism spectrum disorder. Applies validated screening tools, coordinates school-based services, and integrates collaborative care models for mental health in the pediatric primary care setting.

## Why This Skill Exists

Mental health conditions affect 1 in 5 children, but fewer than half receive treatment. Pediatric primary care is the de facto mental health system for most children — wait times for child psychiatry average 6-8 months in many regions. The AAP and AACAP have promoted collaborative care models and universal mental health screening in primary care. This skill ensures every well-child and concern-driven visit includes validated screening, risk stratification, evidence-based initial management, and appropriate referral pathways.

---

## Checkpoint A — Intake Verification

### Required Intake Questions
1. What is the child's age (screening tools are age-specific)?
2. What is the primary behavioral/emotional concern (as described by parent, teacher, and/or child)?
3. When did symptoms begin and what was the temporal context (life event, school change, family stressor)?
4. How are symptoms affecting function (school performance, peer relationships, family dynamics, daily activities)?
5. Is there a family history of anxiety, depression, bipolar disorder, substance use, or suicide?
6. Has the child experienced trauma, abuse, neglect, or significant adverse childhood experiences?
7. Is the child currently receiving any behavioral health services (therapy, medication, school-based)?
8. What is the sleep pattern (insomnia, nightmares, excessive sleep)?
9. Are there any safety concerns (self-harm, suicidal ideation, aggression, homicidal ideation)?

### Required Documents
- Completed screening questionnaires (PHQ-A, GAD-7, SCARED, PSC, ACE questionnaire)
- School records: report cards, behavioral reports, IEP/504 plan
- Prior behavioral health evaluations or therapy notes
- Medication history for psychotropic medications
- Family psychosocial history

---

## Step 1 — Universal Screening (Bright Futures Schedule)

### Recommended Screening Tools by Age and Condition

| Age | Screening Tool | Target Condition |
|-----|---------------|-----------------|
| All ages | Pediatric Symptom Checklist (PSC-17 or PSC-35) | General psychosocial function |
| 1-18 months | ASQ:SE-2 | Social-emotional development |
| 4-17 | ACEs questionnaire (PEARLS or similar) | Adverse childhood experiences |
| 8-17 | PHQ-2 → PHQ-A (if positive) | Depression |
| 8-17 | SCARED (Screen for Child Anxiety Related Disorders) | Anxiety |
| 12-18 | CRAFFT 2.1 | Substance use |
| 18-24 months | M-CHAT-R/F | Autism spectrum disorder |
| Any age with concern | Columbia Suicide Severity Rating Scale (C-SSRS) | Suicidal ideation/behavior |

### Bright Futures Mental Health Screening Schedule
- Depression screening: universally at age 12+ per USPSTF; earlier if clinical concern
- Psychosocial screening: at every well-child visit (surveillance); formal screening per PSC at 4, 5, 6, 8, 10, 12, 14, 16, 18 years
- Substance use: annually starting at age 12 (CRAFFT)
- ACEs: at least once; ideally at initial visit and during high-risk periods

---

## Step 2 — Anxiety Disorders

### Common Presentations by Age
| Age | Common Anxiety Presentation |
|-----|---------------------------|
| Preschool | Separation anxiety, selective mutism |
| School-age | Generalized anxiety, social anxiety, specific phobias |
| Adolescent | Social anxiety, generalized anxiety, panic disorder |

### SCARED Screening
- 41 items, parent and child versions; scores ≥ 25 (child) suggest significant anxiety
- Subscales: panic/somatic, generalized anxiety, separation anxiety, social anxiety, school avoidance
- Administer both parent and child versions for concordance analysis

### Management
- **Mild-moderate**: cognitive behavioral therapy (CBT) is first-line; evidence from CAMS study shows CBT alone effective in 60% of pediatric anxiety
- **Moderate-severe or CBT-insufficient**: SSRI medication
  - Fluoxetine: 5-10 mg → titrate to 20-40 mg (FDA-approved for OCD in children ≥ 7)
  - Sertraline: 12.5-25 mg → titrate to 50-200 mg (FDA-approved for OCD in children ≥ 6)
  - Escitalopram: 5 mg → titrate to 10-20 mg (FDA-approved for depression ≥ 12)
- **Combined CBT + SSRI**: superior to either alone in moderate-severe anxiety (CAMS study)
- Monitor for activation syndrome in first 2-4 weeks of SSRI (agitation, insomnia, worsening anxiety — not the same as suicidality)

### FDA Black Box Warning
- All antidepressants carry FDA black box warning for increased suicidal thinking/behavior in children and adolescents
- Monitor closely: weekly for first 4 weeks, biweekly for next 4, monthly thereafter
- Benefits of treatment generally outweigh risks for moderate-severe anxiety/depression

---

## Step 3 — Depression

### PHQ-A (Patient Health Questionnaire for Adolescents) Interpretation
| Score | Severity | Action |
|-------|----------|--------|
| 0-4 | Minimal | Continued surveillance |
| 5-9 | Mild | Active monitoring; consider CBT |
| 10-14 | Moderate | CBT and/or SSRI; behavioral health referral |
| 15-19 | Moderately severe | SSRI + therapy; expedited referral |
| 20-27 | Severe | Urgent referral; safety assessment |

### Always Ask Question 9
- PHQ-A item 9: "Thoughts that you would be better off dead or hurting yourself in some way"
- ANY positive response requires immediate safety assessment using C-SSRS
- Determine: passive ideation vs. active ideation; plan; means; intent; timeline
- If active ideation with plan: do not leave child unsupervised; initiate crisis intervention

### Treatment
- **Mild depression**: active monitoring, psychoeducation, lifestyle interventions (exercise, sleep hygiene, social connection), supportive therapy
- **Moderate-severe**: fluoxetine (only SSRI with FDA approval for depression in children ≥ 8) + CBT or interpersonal therapy (IPT-A)
- Fluoxetine dosing: start 10 mg/day; may increase to 20 mg after 1-2 weeks if tolerated
- If fluoxetine fails or is not tolerated: escitalopram, sertraline, or citalopram as alternatives
- Avoid: paroxetine (negative studies in pediatrics), TCAs (cardiac risk), benzodiazepines for depression

---

## Step 4 — Disruptive Behavior Disorders

### Oppositional Defiant Disorder (ODD)
- Pattern of angry/irritable mood, argumentative/defiant behavior, vindictiveness lasting ≥ 6 months
- Differentiate from ADHD (impulsivity-driven defiance vs. deliberate opposition), anxiety (avoidance-driven refusal), and trauma (hyperarousal-driven aggression)
- **Management**: parent management training (PMT) is the evidence-based treatment
  - Programs: Triple P, Incredible Years, Parent-Child Interaction Therapy (PCIT)
  - No FDA-approved medication for ODD; treat comorbid conditions (ADHD, anxiety)

### Conduct Disorder (CD)
- Persistent pattern of violating rights of others or age-appropriate societal norms
- Four categories: aggression to people/animals, destruction of property, deceitfulness/theft, serious rule violations
- Risk factors: family dysfunction, poverty, harsh parenting, peer deviance, callous-unemotional traits
- **Management**: multisystemic therapy (MST), functional family therapy, therapeutic foster care; psychiatric referral for severe cases

---

## Step 5 — Adverse Childhood Experiences (ACEs) and Trauma

### ACEs Screening
- Original ACE study (Felitti 1998): 10-item questionnaire covering abuse, neglect, household dysfunction
- PEARLS (Pediatric ACEs and Related Life-events Screener): expanded validated tool for clinical use
- ACE score ≥ 4: associated with dramatically increased risk of: depression, substance use, suicide attempts, chronic disease, early death
- Screening identifies toxic stress exposure; does not diagnose PTSD

### Trauma-Informed Response
- Acknowledge the disclosure; express support without judgment
- Assess current safety (is the child currently in a safe environment?)
- Mandatory reporting if ongoing abuse or neglect is disclosed
- Refer for trauma-focused CBT (TF-CBT) — the most evidence-based therapy for pediatric PTSD
- Screening for trauma should NOT be a one-time event — revisit at subsequent visits

### Building Resilience
- Stable, nurturing caregiver relationship is the strongest protective factor
- Encourage extracurricular activities, community connections, mentorship
- Address caregiver stress and mental health (two-generation approach)

---

## Step 6 — School-Based Coordination

### School-Based Services
- 504 plan: for mental health conditions that substantially limit a major life activity (learning, concentrating, socializing)
- IEP: if emotional disturbance qualifies under IDEA category "Emotional Disturbance" (ED)
- School-based counseling, social skills groups, behavioral intervention plans

### Communication with Schools
- Obtain signed release of information from parent/guardian before communicating with school
- Provide written recommendations for accommodations (specific, actionable)
- Common accommodations: extended time, testing in separate room, reduced homework load, check-in with counselor, movement breaks, social skills groups

### Crisis Planning
- Safety plan for children with suicidal ideation or self-harm: should exist at home AND school
- Safety plan components: warning signs, internal coping strategies, social contacts, adults who can help, professionals to contact, means restriction

---

## Checkpoint B — Behavioral Health Review

- [ ] Universal screening completed per Bright Futures schedule (PSC, PHQ-A, SCARED)
- [ ] Positive screens followed up with validated assessment tools
- [ ] Safety assessment completed (suicidal ideation, self-harm, homicidal ideation)
- [ ] ACEs/trauma history obtained
- [ ] Diagnosis established using DSM-5 criteria
- [ ] Evidence-based treatment initiated (CBT, parent training, SSRI per indication)
- [ ] FDA black box counseling documented (if SSRI prescribed)
- [ ] SSRI monitoring schedule established (weekly × 4, biweekly × 4, then monthly)
- [ ] School accommodations addressed (504/IEP referral, teacher communication)
- [ ] Family psychoeducation provided
- [ ] Follow-up plan specified with interval and escalation criteria
- [ ] All [VERIFY] flags resolved or escalated

---

## Quality Audit

| Item | Requirement | Pass? |
|------|-------------|-------|
| Screening completeness | Age-appropriate screening tool administered | |
| Safety assessment | Suicidal ideation directly assessed; C-SSRS if positive | |
| ACEs screening | Trauma history obtained | |
| Diagnostic rigor | DSM-5 criteria explicitly applied | |
| Treatment evidence | CBT/PMT/SSRI per guideline (not empiric benzodiazepines) | |
| SSRI monitoring | Black box counseling + monitoring schedule documented | |
| School coordination | Release signed; accommodations communicated | |
| Family involvement | Psychoeducation provided; caregiver mental health assessed | |
| Crisis plan | Safety plan created if suicidal ideation or self-harm | |
| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |

---

## Guidelines

- Follow AAP 2018 Mental Health Competencies for Pediatric Practice
- Apply USPSTF recommendation for depression screening in adolescents (grade B, ages 12-18)
- Use PHQ-A (modified PHQ-9 for adolescents) as primary depression screen
- Use SCARED as primary anxiety screen (validated for ages 8-18)
- Follow AACAP Practice Parameters for: anxiety (2007), depression (2007), ODD/CD (2007), PTSD (2010)
- CAMS study: combined CBT + sertraline superior to either alone for moderate-severe pediatric anxiety
- TADS study: combined fluoxetine + CBT superior for adolescent depression; fluoxetine alone superior to CBT alone for depression
- Fluoxetine is the only SSRI with FDA approval for pediatric depression (ages ≥ 8)
- FDA black box: monitor all antidepressants closely for suicidal thinking in children/adolescents
- Collaborative care models (e.g., MCPAP, Project ECHO): leverage psychiatric consultation for primary care-based management
- Never prescribe benzodiazepines for pediatric anxiety or depression as first-line treatment
- This skill produces clinical documentation; it does not replace clinical judgment